Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations)

被引：0
|
作者：
Savitz, A. [1 ]
Xu, H. [2 ]
Gopal, S. [1 ]
Nuamah, I. [2 ]
Hough, D. [1 ]
Hargarter, L. [3 ]
机构：
[1] Janssen Res & Dev, Cent Nervous Syst, Titusville, FL USA
[2] Janssen Res & Dev, Clin Biostats NJ, Titusville, FL USA
[3] Janssen Cilag, Med & Sci Affairs, Neuss, Germany
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷
关键词：
D O I：
10.1016/S0924-977X(16)31590-5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.029
引用
收藏
页码：S546 / S547
页数：2
相关论文
共 50 条
  • [41] SWITCHING SCENARIOS FOR PALIPERIDONE PALMITATE 3-MONTH FORMULATION IN SCHIZOPHRENIA: A POPULATION PHARMACOKINETIC SIMULATION-BASED EVALUATION
    Gopal, S.
    Vermeulen, A.
    Nandy, P.
    Ravenstijn, P.
    Nuamah, I.
    Vidal, J.
    Berwaerts, J.
    Savitz, A.
    Hough, D.
    Samtani, M.
    Russu, A.
    Reeve-Parker, K.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2017, 51 : 161 - 162
  • [42] Switching Scenarios for Paliperidone Palmitate 3-month Formulation in Schizophrenia: A Population Pharmacokinetic Simulation-based Evaluation
    Gopal, Srihari
    Vermeulen, An
    Nandy, Partha
    Ravenstijn, Paulien
    Nuamah, Isaac
    Vidal, Jose Antonio Buron
    Savitz, Adam
    Hough, David
    Samtani, Mahesh N.
    Russu, Alberto
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 72S - 72S
  • [43] Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population
    Russu, Alberto
    Mathews, Maju
    Savitz, Adam
    Gopal, Srihari
    Feng, Yu
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 242 - 242
  • [44] Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia A Randomized Clinical Trial
    Berwaerts, Joris
    Liu, Yanning
    Gopal, Srihari
    Nuamah, Isaac
    Xu, Haiyan
    Savitz, Adam
    Coppola, Danielle
    Schotte, Alain
    Remmerie, Bart
    Maruta, Nataliya
    Hough, David W.
    JAMA PSYCHIATRY, 2015, 72 (08) : 830 - 839
  • [45] Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
    Giron-Hernandez, Cesar
    Han, Joong Hee
    Alberio, Roberta
    Singh, Arun
    Garcia-Portilla, Maria Paz
    Pompili, Maurizio
    Knight, R. Karl
    Richarz, Ute
    Gopal, Srihari
    Antunes, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 895 - 906
  • [46] A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
    Najarian, Dean
    Sanga, Panna
    Wang, Steven
    Lim, Pilar
    Singh, Arun
    Robertson, Mary Jane
    Cohen, Kristin
    Schotte, Alain
    Milz, Ruth
    Venkatasubramanian, Raja
    T'Jollyn, Huybrecht
    Walling, David P.
    Galderisi, Silvana
    Gopal, Srihari
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2022, 25 (03): : 238 - 251
  • [47] Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting
    Di Lorenzo, Rosaria
    Cameli, Michela
    Piemonte, Chiara
    Bolondi, Marisa
    Landi, Giulia
    Pollutri, Gabriella
    Spattini, Ludovica
    Moretti, Valentina
    Ferri, Paola
    NORDIC JOURNAL OF PSYCHIATRY, 2018, 72 (03) : 214 - 220
  • [48] SYMPTOMATIC REMISSION WITH PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA PATIENTS IN A CLINICAL PRACTICE SETTING
    Garcia-Portilla, M. P.
    Llorca, P. M.
    Maina, G.
    Bozikas, V. P.
    Devrimci-Ozguven, H.
    Kim, S. W.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    Najarian, Dean
    Pungor, K.
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S295 - S296
  • [49] Influence of paliperidone palmitate one-month treatment on the medication preference of Chinese patients with acute schizophrenia
    Si, T. M.
    Zhang, L. L.
    Feng, Y.
    Zhuo, J. M.
    Lu, H. F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S544 - S545
  • [50] COST-UTILITY ANALYSIS OF INJECTABLE PALIPERIDONE PALMITATE 3-MONTH FORMULATION VERSUS INJECTABLE RISPERIDONE AND ORAL ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA IN COLOMBIA
    Amezquita, M.
    Alzate, M.
    Cordoba, R.
    Oviedo, G.
    Lopez-Jaramillo, C.
    Guerrero, E.
    Aguirre, A.
    VALUE IN HEALTH, 2018, 21 : S185 - S185
12345